Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.
Schell M, Pflüger I, Brugnara G, Isensee F, Neuberger U, Foltyn M, Kessler T, Sahm F, Wick A, Nowosielski M, Heiland S, Weller M, Platten M, Maier-Hein KH, Von Deimling A, Van Den Bent MJ, Gorlia T, Wick W, Bendszus M, Kickingereder P.
Schell M, et al. Among authors: kickingereder p.
Neuro Oncol. 2020 Nov 26;22(11):1667-1676. doi: 10.1093/neuonc/noaa120.
Neuro Oncol. 2020.
PMID: 32393964
Free PMC article.
Clinical Trial.